This suggests that this enrichment is specific to colorectal cancer and may reflect the higher apparent positive selection for TP53 mutations in colorectal cancer compared with endometrial cancers in general with 57% (4,677/7,345) TP53 mutants in colorectal cancer versus 48% (974/2,045) TP53 mutants in endometrial cancer (P < 0.001, Fisher's exact test). The gene discussed is TP53; the disease is endometrial cancer.